We identified 12 ACMG SF v2.0 genetic variants in 23 of 499 normal subjects (4.6%), and 7 genetic variants were identified in 9 of 159 cancer patients (5.6%) (Fig. 1C, Supplementary Table 2), including BRCA1, KCNH2, MLH1, SCN5A, DSP, GLA, and MSH6. Four of these 7 genetic variants, including KCNH2, SCN5A, DSP, and GLA, were associated with cardiovascular diseases. This evidence concerns the gene MLH1 and cancer.